Rheumatology
| Rheumatoid Arthritis
Rheumatology
Rheumatoid Arthritis
Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: 52-Week Results
book_2
Source:
ACR Convergence 2020 - Poster session - Abs #0208
calendar_today
Published on Medfyle:
November 2020
headphones
1
min
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- FINCH 1 assessed filgotinib efficacy and safety in patients with rheumatoid arthritis and inadequate response to methotrexate (MTX-IR).
- Through Week 52, both filgotinib 100 and 200 mg showed sustained efficacy based on clinical and patient-reported outcomes and radiographic progression and appeared comparable to adalimumab.
- Herpes zoster was observed in all treatment groups with a numeric increase in the filgotinib 200 mg group compared with adalimumab after Week 24.
- Treatment with either dose of filgotinib was well tolerated in MTX-IR patients and no new safety signals were detected through Week 52.
Presenting Author
Read more
arrow_downward
Hide
arrow_upward
Bernard Combe, MD, PhD
CHU Montpellier, Montpellier University
Montpellier
France
Presenter disclosures
Read more
arrow_downward
Hide
arrow_upward
B. Combe, AbbVie, Janssen, Eli Lilly, Novartis, Gilead Sciences, Inc., Roche-Chugai, Sanofi, Pfizer, MSD, Bristol-Myers Squibb